共 57 条
[1]
Sherif A(2005)Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 202-206
[2]
Holmberg L(2004)Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 297-303
[3]
Rintala E(2011)Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003–2007 J Urol 185 72-78
[4]
Fedeli U(2007)Low incidence of perioperative chemotherapy for stage III bladder cancer 1998–2003: a report from the National Cancer Data Base J Urol 178 451-454
[5]
Fedewa SA(2011)Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 252-258
[6]
Ward EM(1993)Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors Ann Oncol 4 403-407
[7]
David KA(2001)Randomized Phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor J Clin Oncol 19 2638-2646
[8]
Milowsky MI(2015)Refining patient selection for neoadjuvant chemotherapy before radical cystectomy J Urol 191 40-47
[9]
Ritchey J(2011)A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Lancet Oncol 12 211-214
[10]
Porter MP(2014)Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 1895-1901